Document is current
Any future updates will be listed below
-
Authors
van der Burg, Stijn J. C.
van de Wal, Deborah
Roets, Evelyne
Steeghs, Neeltje
van Sandick, Johanna W.
Kerst, Martijn
van Coevorden, Frits
Hartemink, Koen J.
Veenhof, Xander A. A. F. A.
Koenen, Anne Miek
Ijzerman, Nikki
van der Graaf, Winette T. A.
Schrage, Yvonne M.
van Houdt, Winan J. https://orcid.org/0000-0002-2303-3468
- License Information
-
More Information
Article History
Received: 9 June 2023
Accepted: 6 September 2023
First Online: 9 October 2023
Disclosure
: N. Steeghs provided consultation or attended advisory boards for Boehringer Ingelheim, Ellipses Pharma, GlaxoSmithKline, Incyte, and Luszana. N. Steeghs received research grants from Abbvie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, CellCentric, Cogent Biosciences, Cresecendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GlaxoSmithKline, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Lixte, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, and Takeda. All were performed outside the submitted work, and all payment was made to the Netherlands Cancer Institute.
